<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878798</url>
  </required_header>
  <id_info>
    <org_study_id>URNN001 / HM20014083</org_study_id>
    <secondary_id>1U01NS095388</secondary_id>
    <nct_id>NCT02878798</nct_id>
  </id_info>
  <brief_title>Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)</brief_title>
  <acronym>TopCSPN</acronym>
  <official_title>Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NeuroNEXT Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TopCSPN trial is a double blinded randomized placebo controlled study of oral topiramate&#xD;
      as a potential disease modifying therapy for cryptogenic sensory peripheral neuropathy&#xD;
      (CSPN). Patients with CSPN who also have metabolic syndrome (defined by the ATPIII criteria)&#xD;
      who do not have an alternative cause for neuropathy will be potentially eligible. The co&#xD;
      primary outcome measures are change in the Norfolk Quality of Life - Diabetic Neuropathy&#xD;
      (NQOL-DN) Scale and intraepidermal nerve fiber density (IEFND) at the distal thigh. The&#xD;
      treatment phase will last 24 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraepidermal nerve fiber density (IENFD)</measure>
    <time_frame>Baseline, 32, 64, 96 weeks, Early Termination</time_frame>
    <description>Difference in IENFD change between treatment groups over 96 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norfolk Quality of Life - Diabetic Neuropathy</measure>
    <time_frame>Screening, 16, 32, 48, 64, 80, 96 weeks</time_frame>
    <description>Difference in NQOL between treatment groups over 96 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief pain inventory - diabetic neuropathy (BPI-DN)</measure>
    <time_frame>Baseline, 16, 32, 48, 64, 80, 96 weeks, Early Termination</time_frame>
    <description>Association of BPI-DN outcomes to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utah Early Neuropathy Scale</measure>
    <time_frame>Screening, 16, 32, 48, 64, 80, 96 weeks, Early Termination</time_frame>
    <description>association of UENS to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sural sensory amplitude (SSA)</measure>
    <time_frame>Baseline, 32, 64, 96 weeks, Early Termination</time_frame>
    <description>association of SSA change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peroneal motor amplitude (PMA)</measure>
    <time_frame>Baseline, 32, 64, 96 weeks, Early Termination</time_frame>
    <description>association of PMA change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peroneal motor conduction velocity (PMCV)</measure>
    <time_frame>Baseline, 32, 64, 96 weeks, Early Termination</time_frame>
    <description>association of PMCV change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>Screening, Baseline, 16, 32, 48, 64, 80, 96 weeks, Early Termination</time_frame>
    <description>association of BMI change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>Screening, 32, 64, 96 weeks, Early Termination</time_frame>
    <description>association of A1C change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Triglycerides (TRG)</measure>
    <time_frame>Screening, 32, 64, 96 weeks, Early Termination</time_frame>
    <description>association of TRG change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>Screening, 32, 64, 96 weeks, Early Termination</time_frame>
    <description>association of LDL change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>Screening, 32, 64, 96 weeks, Early Termination</time_frame>
    <description>association of HDL change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral topiramate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topiramate</intervention_name>
    <description>Oral topiramate at a target dose of 50mg twice daily.</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>overencapsulated placebo of identical color, shape and packaging to topiramate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age 18-80&#xD;
&#xD;
          2. Diagnosis of confirmed symptomatic distal symmetric peripheral polyneuropathy based on&#xD;
             the Toronto consensus criteria for probable neuropathy (the presence of unequivocal&#xD;
             signs and symptoms of neuropathy)45.&#xD;
&#xD;
          3. Evidence of symptomatic neuropathy based on a screening visit NQOL-DN score of &gt;9.&#xD;
&#xD;
          4. Metabolic syndrome based on modified ATPIII criteria. Specific criteria require 3 of&#xD;
             the following 6 to be present at the screening visit.&#xD;
&#xD;
               -  Waist circumference &gt;102 cm for men, &gt;88 cm for women&#xD;
&#xD;
               -  Serum triglycerides of &gt; 150 mg/dl&#xD;
&#xD;
               -  HDL &lt; 40 mg/dl for men, &lt; 50 mg/dl for women&#xD;
&#xD;
               -  Those with either a normal HDL or TRG who are taking a lipid lowering medication&#xD;
                  for this purpose&#xD;
&#xD;
               -  Blood pressure 130/85 mm Hg or use of anti-hypertension drug&#xD;
&#xD;
               -  Hyperglycemia based on American Diabetes Association (ADA) criteria at screening&#xD;
                  based on any one or more of the following: fasting plasma glucose &gt; 100 mg/dL&#xD;
                  (5.6 mmol/L), 2-hour glucose tolerance test &gt; 140 mg/dL (7.8 mmol/L), or&#xD;
                  hemoglobin A1c &gt; 5.7% .&#xD;
&#xD;
          5. No current or prior history of therapy with topiramate.&#xD;
&#xD;
          6. If female of child-bearing potential (i.e., not surgically sterile or post-menopausal&#xD;
             defined as age &gt; 51 years without menses for ≥ 2 years), negative serum pregnancy test&#xD;
             at screening and negative urine pregnancy test at baseline visit.&#xD;
&#xD;
          7. Women of child-bearing potential or men with sexual partners of childbearing potential&#xD;
             be willing to use an acceptable method of birth control for the duration of the study&#xD;
             and for 12 weeks following completion of study drug therapy. Acceptable methods of&#xD;
             birth control include abstinence, oral contraceptives, the contraceptive patch,&#xD;
             intra-uterine device, the contraceptive ring, and or barrier contraception such as&#xD;
             condoms with spermicide.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. CSS-PI clinical determination of an alternative cause for peripheral neuropathy&#xD;
             (including but not limited to rheumatological disorders, Hepatitis B or C, breast&#xD;
             cancer treated with neurotoxic chemotherapy within the past 15 years). All potential&#xD;
             subjects will have screening neuropathy labs including assessment for diabetes&#xD;
             (Hemoglobin A1c, oral glucose tolerance test), vitamin B12 level, and&#xD;
             immunofixation47.&#xD;
&#xD;
          2. Type I diabetes or current use of insulin or use of insulin in the past 3 months.&#xD;
&#xD;
          3. HgA1c &gt; 7.5%. Borderline screening labs can be repeated within two weeks with PPI&#xD;
             approval.&#xD;
&#xD;
          4. History of recurrent nephrolithiasis, a single episode of nephrolithiasis within one&#xD;
             year prior to screening, or use of ongoing preventative treatment.&#xD;
&#xD;
          5. Family history of a hereditary neuropathy in a first-degree relative.&#xD;
&#xD;
          6. Severe neuropathy: Utah Early Neuropathy Score &gt; 24 at screening&#xD;
&#xD;
          7. Active foot ulceration or a history of a nontraumatic foot amputation.&#xD;
&#xD;
          8. ECG with QTc more than 450 ms in men, or 470 ms in women.&#xD;
&#xD;
          9. Risk of excessive bleeding at the skin biopsy site based on the clinical assessment of&#xD;
             the CSS-PI.&#xD;
&#xD;
         10. Chronic corticosteroid use excluding topical or inhaled treatment.&#xD;
&#xD;
         11. Use of a carbonic anhydrase inhibitor (such as acetazolamide) due to risk of&#xD;
             nephrolithiasis.&#xD;
&#xD;
         12. Planned bariatric surgery.&#xD;
&#xD;
         13. Use of other weight loss medications.&#xD;
&#xD;
         14. Use of scheduled opiates, or as needed opiate medications more than three times&#xD;
             weekly.&#xD;
&#xD;
         15. Use of topical capsaicin products within 16 weeks of screening or at any time on&#xD;
             study.&#xD;
&#xD;
         16. Medication change for neuropathy symptoms during the 8 weeks prior to screening; or&#xD;
             anticipated change for the duration of study participation.&#xD;
&#xD;
         17. Current use of an intrathecal pain pump or spinal cord stimulator.&#xD;
&#xD;
         18. Screening laboratory creatinine ≥ 2.0 mg/dl.&#xD;
&#xD;
         19. Severe edema, dermatologic or lower extremity condition that would increase risk of&#xD;
             skin biopsy.&#xD;
&#xD;
         20. Major depression, bipolar affective disorder, or other mental health disorders that&#xD;
             are sufficiently severe to increase adverse event risk or impact neuropathy assessment&#xD;
             in the opinion of the responsible site principal investigator.&#xD;
&#xD;
         21. Current suicidal ideation within one year prior to the baseline visit as evidenced by&#xD;
             answering &quot;yes&quot; to Questions 4 or 5 on the suicidal ideation portion of the&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS).&#xD;
&#xD;
         22. Ataxia sufficiently severe to represent an unacceptable fall risk in the opinion of&#xD;
             the site principal investigator.&#xD;
&#xD;
         23. A serious medical condition expected to dramatically shorten life span or prevent&#xD;
             participation.&#xD;
&#xD;
         24. Any clinically significant condition or illness, which, in the opinion of the CSS-PI,&#xD;
             would pose a risk to the subject or might confound the study including metabolic&#xD;
             acidosis, bone marrow suppression, blood dyscrasias, bleeding disorder, or closed&#xD;
             angle glaucoma.&#xD;
&#xD;
         25. History of alcohol or drug abuse within the past two years, or existing neuropathy&#xD;
             related to past drug or alcohol abuse.&#xD;
&#xD;
         26. History of malignancy within five years prior to study enrollment, except for&#xD;
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.&#xD;
&#xD;
         27. A history of epilepsy.&#xD;
&#xD;
         28. An inability to understand or cooperate with the procedures of the study.&#xD;
&#xD;
         29. Pregnant, or intending to become pregnant, or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Neurology Clinical Trials Organization</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105-2945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

